CN1495166A - 氨氯地平的有机酸盐 - Google Patents
氨氯地平的有机酸盐 Download PDFInfo
- Publication number
- CN1495166A CN1495166A CNA031649564A CN03164956A CN1495166A CN 1495166 A CN1495166 A CN 1495166A CN A031649564 A CNA031649564 A CN A031649564A CN 03164956 A CN03164956 A CN 03164956A CN 1495166 A CN1495166 A CN 1495166A
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- pyroglutamate
- acid
- preparation
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
C25H31N3O8Cl的元素分析(%) | ||||
测量值 | C:55.1 | H:5.9 | N:7.9 | O:22.9 |
计算值 | C:55.7 | H:5.8 | N:7.8 | O:23.8 |
C25H31N3O8Cl的元素分析(%) | ||||
测量值 | C:55.2 | H:5.9 | N:7.8 | O:22.8 |
计算值 | C:55.7 | H:5.8 | N:7.8 | O:23.8 |
C25H31N3O8Cl的元素分析(%) | ||||
测量值 | C:55.0 | H:5.8 | N:7.9 | O:22.9 |
计算值 | C:55.7 | H:5.8 | N:7.8 | O:23.8 |
组分 | 含量(mg每片) |
氨氯地平(S)-(-)-焦谷氨酸盐 | 5.0(基于氨氯地平重量计算) |
低取代的羟丙基纤维素 | 65 |
微晶纤维素 | 120 |
羟乙酸淀粉钠 | 4 |
硬脂酸镁 | 2 |
组分 | 含量(mg每片) |
氨氯地平(S)-(-)-焦谷氨酸盐 | 5.0(基于氨氯地平重量计算) |
乳糖 | 180 |
交联聚乙烯吡咯酮(Cross Povidone) | 6 |
聚乙烯吡咯烷酮 | 6 |
羟乙酸淀粉钠 | 4 |
硬脂酸镁 | 2 |
组分 | 含量(mg每片) |
氨氯地平(S)-(-)-焦谷氨酸盐 | 5.0(基于氨氯地平重量计算) |
低取代的羟丙基纤维素 | 65 |
微晶纤维素 | 120 |
羟乙酸淀粉钠 | 4 |
硬脂酸镁 | 2 |
组分 | 含量(mg每片) |
氨氯地平(S)-(-)-焦谷氨酸盐 | 5.0(基于氨氯地平重量计算) |
乳糖 | 180 |
交联聚乙烯吡咯酮 | 6 |
聚乙烯吡咯烷酮K90 | 6 |
羟乙酸淀粉钠 | 4 |
硬脂酸镁 | 2 |
温度条件(RH) | 25% | 60% | 75% | 90% | |
贮存周期(周) | 初始值 | 1 | 1 | 1 | 1 |
(S)-(-)-焦谷氨酸盐(%) | 0.3 | 0.26 | 0.3 | 0.31 | 0.32 |
苯磺酸盐(%) | 0.14 | 0.10 | 0.09 | 0.15 | 0.17 |
溶剂 | 盐(mg/ml) | 备注 | |
焦谷氨酸盐 | 苯磺酸盐 | ||
蒸馏水 | 500≤ | 2.00 | 离子强度0.2缓冲液在37℃下溶解 |
pH3 | 400≤ | 3.25 | |
pH5 | 400≤ | 3.15 | |
pH6 | 400≤ | 3.19 | |
pH7 | 200≤ | 1.59 | |
pH8 | 200≤ | 1.39 |
盐 | 贮存周期 | |||
初始 | 1周 | 2周 | 3周 | |
焦谷氨酸盐 | 99.6% | 99.6% | 99.5% | 99.2% |
苯磺酸盐 | 99.6% | 99.6% | 99.4% | 99.2% |
盐 | 初始 | 25℃,日光,贮存4周 |
含量(HPLC) | 含量(HPLC) | |
(S)-(-)-焦谷氨酸盐 | 99.5% | 98.5% |
苯磺酸盐 | 99.2% | 82.5% |
甲苯磺酸盐 | 99.2% | 72.0% |
盐酸盐 | 99.0% | 60.5% |
Claims (4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR0049422/2002 | 2002-08-21 | ||
KR10-2002-0049422A KR100467669B1 (ko) | 2002-08-21 | 2002-08-21 | 암로디핀의 유기산염 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1495166A true CN1495166A (zh) | 2004-05-12 |
CN1289482C CN1289482C (zh) | 2006-12-13 |
Family
ID=36643418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031649564A Expired - Fee Related CN1289482C (zh) | 2002-08-21 | 2003-08-21 | 氨氯地平的有机酸盐 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6846931B2 (zh) |
EP (1) | EP1391453B1 (zh) |
JP (1) | JP4319491B2 (zh) |
KR (1) | KR100467669B1 (zh) |
CN (1) | CN1289482C (zh) |
AT (1) | ATE314349T1 (zh) |
AU (1) | AU2003256108A1 (zh) |
DE (1) | DE60302951T2 (zh) |
WO (1) | WO2004018426A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104529877A (zh) * | 2015-01-22 | 2015-04-22 | 华东理工常熟研究院有限公司 | 氨氯地平-癸酸离子液体及其制备方法和用途 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042485A1 (en) * | 2003-10-30 | 2005-05-12 | Sk Chemicals, Co., Ltd. | Acid added salts of amlodipine |
DE102004025373A1 (de) * | 2004-05-24 | 2005-12-15 | Merck Patent Gmbh | Maschinenlesbares Sicherheitselement für Sicherheitserzeugnisse |
EP1695973A1 (en) * | 2005-02-24 | 2006-08-30 | Neuro3D | Ocaperidone salt and pharmaceutical compositions containing the same |
KR101501253B1 (ko) * | 2014-12-22 | 2015-03-12 | 제이투에이치바이오텍 (주) | 결정성 페북소스타트 피돌레이트 염 및 이의 제조 방법 |
EP3960158A1 (en) | 2016-10-07 | 2022-03-02 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
ES2797381T3 (es) * | 2017-07-31 | 2020-12-02 | Small Pharma Ltd | Formas cristalinas de hidroxinorcetamina |
US10799453B2 (en) | 2018-04-11 | 2020-10-13 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US86888A (en) * | 1869-02-09 | Improved clothes-pin | ||
DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
GB8710493D0 (en) | 1987-05-02 | 1987-06-03 | Pfizer Ltd | Dihydropyridines |
US4758569A (en) | 1987-08-26 | 1988-07-19 | Pfizer Inc. | Doxazosin as an anti-atherosclerosis agent |
KR930006256B1 (ko) | 1989-12-28 | 1993-07-09 | 주식회사 코오롱 | 폴리에스테르 결합제의 제조방법 |
US6057344A (en) * | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
AT399718B (de) * | 1992-04-16 | 1995-07-25 | Lek Tovarna Farmacevtskih | Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen |
KR100188391B1 (ko) * | 1993-08-27 | 1999-06-01 | 류정열 | 전기자동차의 충전중 표시 장치 |
KR100217240B1 (ko) * | 1996-10-31 | 1999-09-01 | 조생현 | 암로디핀 베실레이트의 제조방법 |
PL189666B1 (pl) | 1998-04-09 | 2005-09-30 | Adamed Sp Z Oo | Sposób otrzymywania benzenosulfonianu amlodypiny |
JP3590966B2 (ja) | 1999-02-22 | 2004-11-17 | 豊和工業株式会社 | ロッドレスシリンダ |
UA72768C2 (en) * | 1999-07-05 | 2005-04-15 | Richter Gedeon Vegyeszet | A method for obtaining amilodipine benzenesulphonate |
WO2002053538A1 (en) | 2000-12-29 | 2002-07-11 | Pfizer Limited | Amlodipine fumarate |
MXPA03005886A (es) * | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado de aspartato de amlodipina como antagonista del canal de calcio. |
WO2002053542A1 (en) | 2000-12-29 | 2002-07-11 | Pfizer Limited | Process for making amlodipine maleate |
KR100462304B1 (ko) | 2002-07-30 | 2004-12-17 | 씨제이 주식회사 | 암로디핀의 유기산염 |
-
2002
- 2002-08-21 KR KR10-2002-0049422A patent/KR100467669B1/ko not_active IP Right Cessation
-
2003
- 2003-08-19 US US10/642,754 patent/US6846931B2/en not_active Expired - Fee Related
- 2003-08-20 AT AT03018653T patent/ATE314349T1/de not_active IP Right Cessation
- 2003-08-20 EP EP03018653A patent/EP1391453B1/en not_active Expired - Lifetime
- 2003-08-20 DE DE60302951T patent/DE60302951T2/de not_active Expired - Lifetime
- 2003-08-21 JP JP2003297765A patent/JP4319491B2/ja not_active Expired - Fee Related
- 2003-08-21 AU AU2003256108A patent/AU2003256108A1/en not_active Abandoned
- 2003-08-21 CN CNB031649564A patent/CN1289482C/zh not_active Expired - Fee Related
- 2003-08-21 WO PCT/KR2003/001677 patent/WO2004018426A1/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104529877A (zh) * | 2015-01-22 | 2015-04-22 | 华东理工常熟研究院有限公司 | 氨氯地平-癸酸离子液体及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
ATE314349T1 (de) | 2006-01-15 |
DE60302951D1 (de) | 2006-02-02 |
CN1289482C (zh) | 2006-12-13 |
JP4319491B2 (ja) | 2009-08-26 |
KR100467669B1 (ko) | 2005-01-24 |
EP1391453B1 (en) | 2005-12-28 |
WO2004018426A1 (en) | 2004-03-04 |
KR20040017380A (ko) | 2004-02-27 |
EP1391453A1 (en) | 2004-02-25 |
US20040158075A1 (en) | 2004-08-12 |
JP2004131483A (ja) | 2004-04-30 |
DE60302951T2 (de) | 2006-07-20 |
US6846931B2 (en) | 2005-01-25 |
AU2003256108A1 (en) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1023800C (zh) | 一种药物组合物的制备方法 | |
US4983593A (en) | Pharmaceutical composition of dihydropyridine compound | |
EP0869942B1 (en) | 4-((heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents | |
CN1238342C (zh) | 新型氨氯地平樟脑磺酸盐及其制备方法 | |
US5688785A (en) | Substituted azetidinone compounds useful as hypocholesterolemic agents | |
DD144667A5 (de) | Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern | |
DE2445584C3 (de) | L- bzw. DL-2-Methyl-3- (3', 4'-dihydroxyphenyl)-alanin-ester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
CN1845917A (zh) | 3-[(2-{[4-(已氧基羰基氨基-亚氨基-甲基)-苯氨基]-甲基}-1-甲基-1 h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯-甲磺酸酯及其作为药物的用途 | |
CN1289482C (zh) | 氨氯地平的有机酸盐 | |
CN85105301A (zh) | (S)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法 | |
CN1039419A (zh) | 呋喃衍生物制备方法 | |
US20020061931A1 (en) | Stable gabapentin containing more than 20 ppm of chlorine ion | |
NZ523546A (en) | Stable pharmaceutical compositions of gabapentin having PH within the range 6.8 to 7.3 comprising less than 0.5% by weight of a corresponding lactum | |
CN1678584A (zh) | 氨氯地平的有机酸盐 | |
CN1678583A (zh) | 氨氯地平的有机酸盐 | |
CN1152686C (zh) | 稳定化药用组合物 | |
US20100216838A1 (en) | Fexofenadine base polymorphic forms | |
CN1829683A (zh) | 米屈肼盐及其制备方法以及基于米屈肼盐的药物组合物 | |
CN1777586A (zh) | 稳定的无定形樟脑磺酸氨氯地平、其制备工艺以及其口服给药的组合物 | |
CN1956956A (zh) | 龙胆酸氨氯地平及其制备方法 | |
CN1681803A (zh) | 芳酰基-哌啶衍生物 | |
CN1092654C (zh) | 4-苯基哌啶类化合物 | |
CN101528696A (zh) | 晶态s-(-)-氨氯地平无水己二酸盐及其制备方法 | |
KR100496436B1 (ko) | 암로디핀의 유기산염 | |
CN1515553A (zh) | 哌啶衍生物晶体、其制备所用的中间体以及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CJ CHEIL JEDANG CORP. Free format text: FORMER OWNER: CHEIL JEDANG CORP. Effective date: 20080328 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080328 Address after: Seoul, South Kerean Patentee after: CJ Corp. Address before: Seoul, South Kerean Patentee before: First sugar refining Corporation |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061213 Termination date: 20150821 |
|
EXPY | Termination of patent right or utility model |